ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research report released on Thursday morning.

Other research analysts have also issued research reports about the company. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. HC Wainwright increased their target price on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ProQR Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $7.13.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $3.84 on Thursday. The business has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $2.29. The firm has a market capitalization of $313.65 million, a price-to-earnings ratio of -12.00 and a beta of 0.26. ProQR Therapeutics has a one year low of $1.35 and a one year high of $4.62.

Institutional Trading of ProQR Therapeutics

A number of large investors have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. grew its position in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after acquiring an additional 51,663 shares during the period. BNP Paribas Financial Markets lifted its stake in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Finally, OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).